Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pharmacology and Therapeutics

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2010.04.005PMID 20438756
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th edition

  2018cited by this paper
• The Endothelin System

  2012cited by this paper
• Myocardial Basis for Heart Failure

  2011cited by this paper
• Chapter 5 – Myocardial Basis for Heart Failure: Role of the Cardiac Interstitium

  2011cited by this paper
• Cardiac-Specific IGF-1 Receptor Transgenic Expression Protects Against Cardiac Fibrosis and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy

  2010cited by this paper
• PI3K(p110&agr;) Protects Against Myocardial Infarction-Induced Heart Failure: Identification of PI3K-Regulated miRNA and mRNA

  2010cited by this paper
• Comprar Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume, 9th Edition | Robert O. Bonow | 9781437703986 | Saunders

  2010cited by this paper
• The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats

  2009cited by this paper
• Cardioprotection requires taking out the trash

  2009cited by this paper
• Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.

  2009cited by this paper
• Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

  2009cited by this paper
• MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2.

  2009cited by this paper
• Cardiac-Specific Deletion of Mkk4 Reveals Its Role in Pathological Hypertrophic Remodeling but Not in Physiological Cardiac Growth

  2009cited by this paper
• The protective effects of exercise and phosphoinositide 3-kinase (p110alpha) in the failing heart.

  2009cited by this paper
• Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2009cited by this paper
• Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.

  2009cited by this paper
• Targeting histone deacetylases for heart failure

  2009cited by this paper
• MicroRNAs and their role in progressive kidney diseases.

  2009cited by this paper
• Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury.

  2009cited by this paper
• Sex-based cardiac physiology.

  2009cited by this paper
• Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice.

  2009cited by this paper
• Stimulus specific changes of energy metabolism in hypertrophied heart.

  2009cited by this paper
• New insights into the regulation of angiotensin receptors

  2009cited by this paper
• MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.

  2009cited by this paper
• A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy

  2009influential reference
• MicroRNA regulation of cardiovascular development.

  2009cited by this paper
• Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy.

  2009cited by this paper
• Palliative care in congestive heart failure.

  2009cited by this paper
• Regulation of phosphoinositide 3-kinase expression in health and disease.

  2009cited by this paper
• Deficiency of Nectin-2 Leads to Cardiac Fibrosis and Dysfunction Under Chronic Pressure Overload

  2009cited by this paper
• MicroRNA: a new frontier in kidney and blood pressure research.

  2009cited by this paper
• Adaptation of the rat cardiac proteome in response to intensity‐controlled endurance exercise

  2009cited by this paper
• Intercalated discs: multiple proteins perform multiple functions in non-failing and failing human hearts

  2009cited by this paper
• The role of autophagy in the heart

  2009cited by this paper
• Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2009cited by this paper
• The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload

  2009cited by this paper
• Metabolic remodelling of the failing heart: beneficial or detrimental?

  2009cited by this paper
• 생쥐 부정소에서 endothelin system의 발현

  2009cited by this paper
• Loss of Cardiac Phosphoinositide 3-Kinase p110&agr; Results in Contractile Dysfunction

  2009cited by this paper
• Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial.

  2009cited by this paper
• Nectin-2: an intercalated disc protein that maintains cardiac function in a setting of pressure overload.

  2009cited by this paper
• Role of phosphoinositide 3-kinases in regulating cardiac function.

  2009cited by this paper
• Loss of Cardiac microRNA-Mediated Regulation Leads to Dilated Cardiomyopathy and Heart Failure

  2009cited by this paper
• MicroRNAs in Cardiovascular Biology and Heart Disease

  2009cited by this paper
• Estrogen Attenuates Left Ventricular and Cardiomyocyte Hypertrophy by an Estrogen Receptor–Dependent Pathway That Increases Calcineurin Degradation

  2009cited by this paper
• MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat-Shock Protein 20

  2009cited by this paper
• DISTINCT ROLE OF ADRENOCEPTOR SUBTYPES IN CARDIAC ADAPTATION TO CHRONIC PRESSURE OVERLOAD

  2008cited by this paper
• MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets.

  2008cited by this paper
• MicroRNAs: novel regulators in cardiac development and disease.

  2008cited by this paper
• Targeting p38-MAPK in the ischaemic heart: kill or cure?

  2008cited by this paper
• Sarcomeric proteins and inherited cardiomyopathies.

  2008cited by this paper
• G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure

  2008cited by this paper
• Ca2+/Calmodulin-Dependent Protein Kinase II&dgr; and Protein Kinase D Overexpression Reinforce the Histone Deacetylase 5 Redistribution in Heart Failure

  2008cited by this paper
• PROMOTING PHYSIOLOGICAL HYPERTROPHY IN THE FAILING HEART

  2008cited by this paper
• Sarcomeric dysfunction in heart failure.

  2008cited by this paper
• Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under pressure overload

  2008cited by this paper
• Knockout of β1‐ and β2‐adrenoceptors attenuates pressure overload‐induced cardiac hypertrophy and fibrosis

  2008cited by this paper
• Symptom distress and quality of life in patients with advanced congestive heart failure.

  2008cited by this paper
• MicroRNA and cardiac pathologies.

  2008cited by this paper
• Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors

  2008influential reference
• ROLE OF INSULIN‐LIKE GROWTH FACTOR 1 AND PHOSPHOINOSITIDE 3‐KINASE IN A SETTING OF HEART DISEASE

  2008cited by this paper
• The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology.

  2008cited by this paper
• Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy.

  2008cited by this paper
• Proceedings of the Australian Physiological Society Symposium: Influencing Factors in the Fate of Cardiac Myocytes in Heart Disease IMPACT OF MULTIPLE GENE MUTATIONS IN DETERMINING THE SEVERITY OF CARDIOMYOPATHY AND HEART FAILURE

  2008cited by this paper
• Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload.

  2008cited by this paper
• The Emerging Role of MicroRNAs in Cardiac Remodeling and Heart Failure

  2008cited by this paper
• Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation

  2008cited by this paper
• Metabolic remodelling of the failing heart: beneficial or detrimental?

  2008cited by this paper
• Cardiac alpha 1-adrenergic drive in pathological remodelling.

  2008cited by this paper
• Systemic adaptation to oxidative challenge induced by regular exercise.

  2008cited by this paper
• Crosstalk Between Autophagy and Apoptosis in Heart Disease

  2008cited by this paper
• The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice.

  2008cited by this paper
• Requirement of protein kinase D1 for pathological cardiac remodeling

  2008cited by this paper
• The GH–IGF‐I axis and the cardiovascular system: clinical implications

  2008cited by this paper
• Tamoxifen-inducible gene deletion in the cardiac conduction system.

  2008cited by this paper
• Multiplex Kinase Signaling Modifies Cardiac Function at the Level of Sarcomeric Proteins*

  2008cited by this paper
• HDAC4 and PCAF Bind to Cardiac Sarcomeres and Play a Role in Regulating Myofilament Contractile Activity*

  2008cited by this paper
• Role of angiotensin II AT1 receptor activation in cardiovascular diseases.

  2008cited by this paper
• The myocardial JAK/STAT pathway: from protection to failure.

  2008cited by this paper
• MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

  2008cited by this paper
• Role of gp130‐mediated signalling pathways in the heart and its impact on potential therapeutic aspects

  2008cited by this paper
• AT2 receptors: Functional relevance in cardiovascular disease

  2008cited by this paper
• The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

  2008cited by this paper
• Endothelial-to-mesenchymal transition contributes to cardiac fibrosis

  2007cited by this paper
• Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.

  2007cited by this paper
• Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy

  2007cited by this paper
• Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice.

  2007cited by this paper
• Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity

  2007cited by this paper
• Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.

  2007cited by this paper
• Unveiling gender differences in demand ischemia: a study in a rat model of genetic hypertension.

  2007cited by this paper
• A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart.

  2007cited by this paper
• The Fuzzy Logic of Physiological Cardiac Hypertrophy

  2007cited by this paper
• Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis

  2007cited by this paper
• Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis

  2007cited by this paper
• PI3K(p110α) Inhibitors as Anti-Cancer Agents: Minding the Heart

  2007cited by this paper
• CD36 Expression Contributes to Age-Induced Cardiomyopathy in Mice

  2007cited by this paper
• MicroRNA—implications for cancer

  2007cited by this paper
• Mitogen-activated protein kinases in heart development and diseases.

  2007cited by this paper
• Glycogen Synthase Kinase-3α Reduces Cardiac Growth and Pressure Overload-induced Cardiac Hypertrophy by Inhibition of Extracellular Signal-regulated Kinases*

  2007cited by this paper
• Cardiac GPCRs: GPCR signaling in healthy and failing hearts.

  2007cited by this paper

• Efficacy of low dose colchicine on left ventricular hypertrophy in patients with coronary artery disease: A randomized controlled trial.

  2026cites this paper
• Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy

  2026cites this paper
• Thymoquinone Protects Against Cardiac Hypertrophy via PPAR‐γ/PI3K/Akt Pathway

  2026cites this paper
• Phosphatidylinositol 4-Kinase IIIβ: A Therapeutic Target for Contractile Dysfunction in Hypertrophic Cardiomyocytes

  2026cites this paper
• Homeometric autoregulation in severe aortic stenosis: insights from transcatheter aortic valve replacement

  2026cites this paper
• Modulating the myosin super-relaxed state as a therapeutic strategy for myosin light chain–linked cardiomyopathies

  2026cites this paper
• Rigid and soft substrates respectively promote the myocardial differentiation and maturation of human embryonic stem cells using elastic PDMS with thick synthetic coating.

  2025cites this paper
• Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals

  2025cites this paper
• Therapeutic Inhibition of PHF21B Attenuates Pathological Cardiac Hypertrophy by Inhibiting the BMP4/GSK3β/β-Catenin Axis.

  2025cites this paper
• The role of regular physical activity in the reduction of various cardiac risks

  2025cites this paper
• Exposure to polystyrene microplastics with different functional groups: Implications for blood pressure and heart.

  2025cites this paper
• High-Intensity Interval Training Attenuates Inflammation in Cardiorenal Syndrome Induced by Renal Ischemia–Reperfusion Injury in Rats

  2025cites this paper
• Cardiomyocyte-Specific FoxO1 Knockout Mice as Tools to Assess Cardiac Hypertrophy and Key Experimental Considerations Using Cre-loxP.

  2025cites this paper
• In Old Mice, Exercise Induces Inflammation and Fibrosis Unless Alk5‐Inhibitor and Oxytocin Are Used

  2025cites this paper
• Glycolytic Reprogramming in Uterine Fibroids: Genetic, Transcriptomic, Proteomic, and Metabolomic Insights

  2025cites this paper
• Novel model of cardiac hypertrophy with cardiorenal dysfunction

  2025cites this paper
• TRPV2 mediates stress resilience in mouse cardiomyocytes

  2025cites this paper
• Upregulation of miR-223-3p in diabetic cardiomyopathy modulates disease progression via the GRK2/NLRP3 signaling pathway.

  2025cites this paper
• Programming fetal cardiometabolic pathways: the double-edged role of glucocorticoids in heart development

  2025cites this paper
• Effects of (-)-epicatechin in cardiac hypertrophy of male rats obese by programing

  2025cites this paper
• Transcriptomic profiling of cardiac development in Bama Xiang pigs across key developmental stages

  2025cites this paper
• Construction of a deep learning model and identification of the pivotal characteristics of FGF7- and MGST1- positive fibroblasts in heart failure post-myocardial infarction.

  2025cites this paper
• Molecular mechanisms for pathophysiology and therapy of cardiac dysfunction in heart failure

  2025cites this paper
• ATF6β is not essential for the development of physiological cardiac hypertrophy

  2025cites this paper
• Potential preventive effects of selected traditional Chinese medicine as adjuvant therapy on hypertensive heart disease progression by replenishing qi and activating blood circulation: a systematic review and meta-analysis of clinical trials

  2025cites this paper
• MicroRNA mediated regulation in early-onset cardiac hypertrophy: Insights from the hypertrophic heart rat model

  2025cites this paper
• Potential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure: Extracellular Vesicles

  2025cites this paper
• An overview of the multi-dimensional mechanisms of exercise-regulated hormones and growth factors in cardiac physiological adaptation

  2025cites this paper
• Calcium-dependent regulation of physiological vs pathological cardiomyocyte hypertrophy.

  2025cites this paper
• A Narrative Review on the Effect of Exercise on Cardiovascular Health

  2025cites this paper
• The cardiac phospho-proteome during pressure overload in mice

  2025cites this paper
• Structure Optimization of Natural Product Catalpol to Obtain Novel and Potent Analogs against Heart Failure.

  2025cites this paper
• High-Throughput Screening of EGFR/Ca2+ Signaling Modulators in Cardiac Hypertrophy Using a Tetrahedral DNA Nanostructure-Based hESC Platform

  2025cites this paper
• Circular RNA-mediated regulation of key signaling pathways in cardiovascular diseases: a review.

  2025cites this paper
• Engineered Prussian Blue‐Curcumin Nanozyme with RONS Scavenging Properties for Augmented Reversible Treatment of Cardiac Hypertrophy

  2025cites this paper
• Protein interactions, network pharmacology, and machine learning work together to predict genes linked to mitochondrial dysfunction in hypertrophic cardiomyopathy

  2025cites this paper
• Dl-3-n-butylphthalide attenuates acute myocardial infarction by inhibiting the binding of Nrf2/Keap1.

  2025cites this paper
• Predictive value of miR-637 for the occurrence of myocardial hypertrophy in patients with hypertension

  2025cites this paper
• The Network of Exosomes miRNA and p‐MLC2 Regulatory Pathway Induced Pathological Cardiac Hypertrophy in Vasn Deficient Mice

  2025cites this paper
• Intensity, Duration, and Context Dependency of the Responses to Nutrient Surplus and Deprivation Signaling in the Heart: Insights Into the Complexities of Cardioprotection

  2025cites this paper
• Modeling myocardial physiological growth using human pluripotent stem cell derived cardiomyocytes and 3D cardiac microtissues

  2025cites this paper
• Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α

  2025cites this paper
• Crosstalk between MST1-Hippo and Wnt/β-Catenin, Notch, and PI3K/Akt pathways in cardiac physiology and pathology

  2025cites this paper
• Left ventricular mass and systolic function in children environmentally exposed to fluoride.

  2025cites this paper
• Oltipraz ameliorates pressure overload-induced pathological cardiac hypertrophy in mice.

  2025cites this paper
• Pyruvate plus uridine augment mitochondrial respiration and prevent cardiac hypertrophy in zebrafish and H9c2 cells.

  2025cites this paper
• Regulatory effects of resveratrol on nitric oxide signaling in cardiovascular diseases

  2025cites this paper
• n-Butylphthalide alleviates obesity-induced cardiomyopathy by binding directly to Keap1.

  2025cites this paper
• Mitochondrial Dysfunction and Calcium Homeostasis in Heart Failure: Exploring the Interplay Between Oxidative Stress and Cardiac Remodeling for Future Therapeutic Innovations.

  2024cites this paper
• Pathophysiology of Angiotensin II-Mediated Hypertension, Cardiac Hypertrophy, and Failure: A Perspective from Macrophages

  2024cites this paper
• Transcriptional response of the heart to vagus nerve stimulation.

  2024cites this paper
• A Thorough Navigation of miRNA's Blueprint in Crafting Cardiovascular Fate

  2024cites this paper
• miR-421-Mediated Suppression of FGF13 as a Novel Mechanism Ameliorating Cardiac Hypertrophy by Inhibiting Endoplasmic Reticulum Stress.

  2024cites this paper
• Resistance Exercise Training Mitigates Cardiac Remodeling Induced by a High-Fat Diet in Rodents: A Systematic Review

  2024cites this paper
• Inhibiting glycosphingolipids alleviates cardiac hypertrophy by reducing reactive oxygen species and restoring autophagic homeostasis

  2024cites this paper
• FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

  2024cites this paper
• Investigating Inherited Heart Diseases Using Human Induced Pluripotent Stem Cell-Based Models

  2024cites this paper
• TongGuanWan Alleviates Doxorubicin- and Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis by Modulating Apoptotic and Fibrotic Pathways

  2024cites this paper
• MiR-495-3p promotes cardiac hypertrophy by targeting Pum2.

  2024cites this paper
• Sulfur Amino Acid Restriction Mitigates High-Fat Diet-Induced Molecular Alterations in Cardiac Remodeling Primarily via FGF21-Independent Mechanisms

  2024cites this paper
• MAS RECEPTOR BLOCKADE IMPAIRS EXERCISE-INDUCED CARDIAC HYPERTROPHY.

  2024cites this paper
• Dual effect of N-terminal deletion of cardiac myosin essential light chain in mitigating cardiomyopathy

  2024cites this paper
• Effect of Cannabistilbene I in Attenuating Angiotensin II-Induced Cardiac Hypertrophy: Insights into Cytochrome P450s and Arachidonic Acid Metabolites Modulation

  2024cites this paper
• Cytokines as markers of non-functional overstrain in rowing athletes

  2024cites this paper
• The enhancing effects of selenomethionine on harmine in attenuating pathological cardiac hypertrophy via glycolysis metabolism

  2024cites this paper
• Apigenin Attenuates Transverse Aortic Constriction-Induced Myocardial Hypertrophy: The Key Role of miR-185-5p/SREBP2-Mediated Autophagy

  2024cites this paper
• Regulated Cell Death Pathways in Pathological Cardiac Hypertrophy

  2024cites this paper
• Inhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development

  2024cites this paper
• Beneficial Effects of Exercise on Hypertension-Induced Cardiac Hypertrophy in Adolescents and Young Adults

  2024cites this paper
• UCP1‐dependent brown adipose activation accelerates cardiac metabolic remodeling and reduces initial hypertrophic and fibrotic responses to pathological stress

  2024cites this paper
• Knock out of the intracellular calcium conducting ion channel Mitsugumin 23 (MG23) protects against pressure overload induced left ventricular hypertrophy and cardiac dysfunction

  2024cites this paper
• Long non-coding RNA RP11-197K6.1 as ceRNA promotes colorectal cancer progression via miR-135a-5p/DLX5 axis

  2024cites this paper
• Circular RNAs: a small piece in the heart failure puzzle

  2024cites this paper
• The potential roles of exosomes in pathological cardiomyocyte hypertrophy mechanisms and therapy: A review

  2024cites this paper
• Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation

  2024cites this paper
• Titin's cardiac-specific N2B element is critical to mechanotransduction during volume overload of the heart.

  2024cites this paper
• Exercise-induced cardiac mitochondrial reorganization and enhancement in spontaneously hypertensive rats

  2024cites this paper
• Regulation of H9C2 cell hypertrophy by 14-3-3η via inhibiting glycolysis

  2024cites this paper
• RNA-mediated epigenetic regulation in exercised heart: Mechanisms and opportunities for intervention.

  2024cites this paper
• Stromal Cell-SLIT3/Cardiomyocyte-ROBO1 Axis Regulates Pressure Overload-Induced Cardiac Hypertrophy

  2024cites this paper
• Aerobic Exercise Attenuates Pressure Overload–Induced Myocardial Remodeling and Myocardial Inflammation via Upregulating miR-574-3p in Mice

  2024cites this paper
• RICH1 is a novel key suppressor of isoproterenol‑ or angiotensin II‑induced cardiomyocyte hypertrophy

  2024cites this paper
• Protective Effects of METRNL overexpression against pathological cardiac remodeling.

  2024cites this paper
• CTRP3 alleviates mitochondrial dysfunction and oxidative stress injury in pathological cardiac hypertrophy by activating UPRmt via the SIRT1/ATF5 axis

  2024cites this paper
• Dronedarone Attenuates Ang II-Induced Myocardial Hypertrophy Through Regulating SIRT1/FOXO3/PKIA Axis

  2024cites this paper
• Inherited physical capacity: Widening divergence from young to adult to old

  2024cites this paper
• Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension

  2024cites this paper
• Role of myocardial microRNAs in the long-term ventricular remodelling of patients with aortic stenosis

  2024cites this paper
• O Treinamento Resistido Atenua a Remodelação Cardíaca Induzida por uma Dieta Hiperlipídica em Roedores: Uma Revisão Sistemática

  2024cites this paper
• Sex-specific regulation of the cardiac transcriptome by the protein phosphatase 2A regulatory subunit B55α

  2024cites this paper
• Role of Vasoactive Hormone-Induced Signal Transduction in Cardiac Hypertrophy and Heart Failure

  2024cites this paper
• Mechanism of Astragalus membranaceus (Huangqi, HQ) for treatment of heart failure based on network pharmacology and molecular docking

  2024cites this paper
• The Effects of 16-HETE Enantiomers on Hypertrophic Markers in Human Fetal Ventricular Cardiomyocytes, RL-14 Cells

  2023cites this paper
• PKD knockdown mitigates Ang II-induced cardiac hypertrophy and ferroptosis via the JNK/P53 signaling pathway.

  2023cites this paper
• CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signaling pathway

  2023cites this paper
• The Potential Role of Nutrition in Overtraining Syndrome: A Narrative Review

  2023cites this paper
• Adaptive and maladaptive roles of different angiotensin receptors in the development of cardiac hypertrophy and heart failure.

  2023cites this paper
• The Regulatory Effect of Receptor-Interacting Protein Kinase 3 on CaMKIIδ in TAC-Induced Myocardial Hypertrophy

  2023cites this paper
• Deep phenotyping of miRNAs in exercise-induced cardiac hypertrophy and fibrosis

  2023cites this paper
• The sinoatrial node extracellular matrix promotes pacemaker phenotype and protects automaticity in engineered heart tissues from cyclic strain

  2023cites this paper